Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection: A single-center experience

BACKGROUND Despite the rapid spread of the infection, there is still limited of evidence on maternal and perinatal outcomes of Pregnant Women with SARS-COV-2 METHODS This was a single-center, cohort study on SARS-CoV-2 in pregnancy. Pregnant women with laboratory-confirmed SARS-CoV-2 from 1 August 2020 to 1 January 2021 from University of Naples Federico II were included in the study. A confirmed case of COVID-19 was defined as a positive result on real-time reverse-transcriptase-polymerase-chain-reaction (RTPCR) assay of nasal and pharyngeal swab specimens. The primary outcome was the incidence preterm birth. RESULTS 249 singleton pregnancies, positive to SARS-CoV-2 at RT-PCR nasal and pharyngeal swab, were included in the study. Mean gestational age at diagnosis was 35.1 ± 5.7 weeks, with 0.8% of women being diagnosed in the first, 11.6% in the second and 218% in the third trimester of pregnancy. Mean gestational age at diagnosis was 34.2± 6.9 weeks, with 2.4% of women being diagnosed in the first, 14.1% in the second and 83.4% in the third trimester of pregnancy. The vast majority of the women received therapy with low molecular weight heparin (88.8%). 47 women (18.9%) required oxygen therapy. The rate of admission to maternal intensive care unit was 2.8%. There was one case of maternal death, accounting for a maternal mortality rate of 0.4%. Out of the 249 completed pregnancies, we reported two spontaneous abortion and two stillbirths. Among the 245 live-born babies, no neonatal deaths were recorded. All babies were tested negative at RT-PCR nasal and pharyngeal swab. The incidence of preterm delivery before 37 weeks was 10%.u CONCLUSIONS SARS-CoV-2 infection in pregnant women is associated with relative low rate of maternal and perinatal adverse outcome.